Drug Type Bispecific antibody |
Synonyms anti-PD-L1/TGFbeta bispecific antibody(Mabworks Biotech), bispecific antibody targeting PD-L1 and TGFbeta(Mabworks Biotech), dual PD-L1 checkpoint inhibitor/TGFbeta inhibitor(M) + [1] |
Target |
Action inhibitors |
Mechanism PDL1 inhibitors(Programmed death-ligand 1 inhibitors), TGF-β inhibitors(Transforming growth factor beta inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseDiscovery |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Small Cell Lung Cancer | Discovery | China | - | |
Stomach Cancer | Discovery | China | - |